Extended-release tacrolimus tablets for preventing organ transplant rejection
| Autor: | Daniel C. Brennan, Timothy A. Horwedel |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Population 030232 urology & nephrology Organ transplant rejection chemical and pharmacologic phenomena 030230 surgery Pharmacology 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Medicine Pharmacology (medical) Adverse effect education Intensive care medicine Pharmacology Toxicology and Pharmaceutics (miscellaneous) education.field_of_study business.industry Health Policy Immunosuppression Tacrolimus Transplantation surgical procedures operative Pharmacogenomics business |
| Zdroj: | Expert Opinion on Orphan Drugs. 4:1079-1086 |
| ISSN: | 2167-8707 |
| DOI: | 10.1080/21678707.2016.1218330 |
| Popis: | Introduction: Tacrolimus has been used for prophylaxis of organ rejection since 1994, and has become a mainstay of immunosuppressive therapy. Tacrolimus XR tablets were released in the U.S. in 2015 and offer greater bioavailability and less variability in daily exposure as compared to other available tacrolimus formulations. These pharmacokinetic differences may offer transplant recipients several unique advantages, including potential for more predictable immunosuppression.Areas covered: Tacrolimus XR is discussed in the kidney transplant population, as these present the largest population in which it has been studied and demonstrates the key differences compared to other formulations. Several key studies are analyzed to determine key patients that will benefit from these more predictable kinetics. Additionally, tacrolimus XR may offer benefit for patients experiencing neurotoxicity. Here we review the potential mechanisms for this adverse effect, as well as available literature regarding managem... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|